YU70803A - Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa - Google Patents
Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensaInfo
- Publication number
- YU70803A YU70803A YU70803A YUP70803A YU70803A YU 70803 A YU70803 A YU 70803A YU 70803 A YU70803 A YU 70803A YU P70803 A YUP70803 A YU P70803A YU 70803 A YU70803 A YU 70803A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- formula
- compounds
- cell
- adhesion
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
Abstract
Ovaj pronalazak se odnosi na nove derivate imidazolidina, formule (I): u kojoj A, E, Z, R1, R2, R3, R4 i R5 imaju znacenja kao sto je navedeno u zahtevima. Jedinjenja formule I su znacajna farmaceutski aktivna jedinjenja koja su pogodna, na primer, za lecenje inflamatorna oboljenja, recimo reumatoidnog artritisa ili alergijskih oboljenja. Jedinjenja formule (I) su inhibitori adhezije i migracije leukocita i/ili antagonisti adhezije receptora VLA-4 koji pripadaju grupi inergina. Generalno ova jedinjenja su pogodna za lecenje oboljenja koja su uzrokvoana adhezijom leukocita i/ili migracijom leukocita do nezeljnih razmera ili su sa ovim povezana ili za lecenje oboljenja u kojima interakcije celija-celija ili celija-matriks, zasnovane na interakcijama VLA-4 receptora sa ligandima, imaju vaznu ulogu. Pronalazak se dalje odnosi na proces dobijanja jedinjenja formule (I), upotrebu ovih jedinjenja i farmaceutske preparate koji sadrze jedinjenja formule (I).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10111877A DE10111877A1 (de) | 2001-03-10 | 2001-03-10 | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU70803A true YU70803A (sh) | 2006-05-25 |
| RS51140B RS51140B (sr) | 2010-10-31 |
Family
ID=7677184
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6680333B2 (sh) |
| EP (1) | EP1373249B1 (sh) |
| JP (1) | JP4482277B2 (sh) |
| KR (1) | KR100991678B1 (sh) |
| CN (1) | CN1227248C (sh) |
| AR (1) | AR035692A1 (sh) |
| AT (1) | ATE293621T1 (sh) |
| AU (1) | AU2002233358B2 (sh) |
| BG (1) | BG108134A (sh) |
| BR (1) | BR0207981A (sh) |
| CA (1) | CA2440648C (sh) |
| CZ (1) | CZ301893B6 (sh) |
| DE (2) | DE10111877A1 (sh) |
| DK (1) | DK1373249T3 (sh) |
| EE (1) | EE05401B1 (sh) |
| ES (1) | ES2240687T3 (sh) |
| HK (1) | HK1062173A1 (sh) |
| HR (1) | HRP20030713B1 (sh) |
| HU (1) | HU228304B1 (sh) |
| IL (2) | IL157830A0 (sh) |
| ME (1) | MEP61108A (sh) |
| MX (1) | MXPA03007634A (sh) |
| MY (1) | MY129029A (sh) |
| NO (1) | NO326001B1 (sh) |
| NZ (1) | NZ528075A (sh) |
| PE (1) | PE20020904A1 (sh) |
| PL (1) | PL204622B1 (sh) |
| PT (1) | PT1373249E (sh) |
| RS (1) | RS51140B (sh) |
| RU (1) | RU2303592C2 (sh) |
| SI (1) | SI1373249T1 (sh) |
| SK (1) | SK286652B6 (sh) |
| TW (1) | TWI328587B (sh) |
| WO (1) | WO2002072573A1 (sh) |
| ZA (1) | ZA200306107B (sh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19647380A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| AU3906300A (en) * | 1999-03-22 | 2000-10-09 | Ortho-Mcneil Pharmaceutical, Inc. | Process of preparing 3s-3-amino-3-aryl propionic acid and derivatives thereof |
| US20070043078A1 (en) * | 2003-10-10 | 2007-02-22 | Kowa Co., Ltd. | Angiogenesis inhibitor |
| CA2723358A1 (en) * | 2008-05-05 | 2009-11-12 | Allison B. Reiss | Method for improving cardiovascular risk profile of cox inhibitors |
| WO2012061074A1 (en) | 2010-10-25 | 2012-05-10 | Elan Pharmaceuticals, Inc. | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS |
| CN112707874A (zh) * | 2020-12-29 | 2021-04-27 | 广东中科药物研究有限公司 | 一种抗病毒化合物及其制备方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4009506A1 (de) | 1990-03-24 | 1991-09-26 | Hoechst Ag | Hydantoinderivate |
| DE4126277A1 (de) | 1991-08-08 | 1993-02-11 | Cassella Ag | Hydantoinderivate |
| ES2102009T5 (es) | 1992-01-13 | 2004-12-16 | Biogen Inc | Tratamiento para el asma. |
| ES2103468T3 (es) | 1992-02-12 | 1997-09-16 | Biogen Inc | Tratamiento de la inflamacion intestinal. |
| DE4207254A1 (de) | 1992-03-07 | 1993-09-09 | Cassella Ag | 4-oxo-2-thioxoimidazolidin-derivate |
| DE4213634A1 (de) | 1992-04-24 | 1993-10-28 | Cassella Ag | 2,4-Dioxo-imidazolidin-Derivate |
| DE4224414A1 (de) | 1992-07-24 | 1994-01-27 | Cassella Ag | Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung |
| DE4228717A1 (de) | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidin-Derivate |
| WO1994015958A2 (en) | 1993-01-08 | 1994-07-21 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
| JPH08507680A (ja) | 1993-01-12 | 1996-08-20 | バイオジェン インコーポレイテッド | 組換え抗ｖｌａ４抗体分子 |
| EP0682529B2 (en) | 1993-02-09 | 2005-12-28 | Biogen Idec MA, Inc. | Antibody for the treatment of insulin dependent diabetes |
| DE4308034A1 (de) | 1993-03-13 | 1994-09-15 | Cassella Ag | Neue Heterocyclen, ihre Herstellung und ihre Verwendung |
| DE4427979A1 (de) | 1993-11-15 | 1996-02-15 | Cassella Ag | Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung |
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| EP1759709B1 (en) | 1994-01-25 | 2013-02-27 | Elan Pharmaceuticals Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| JPH10502349A (ja) | 1994-06-29 | 1998-03-03 | テキサス・バイオテクノロジー・コーポレイシヨン | インテグリンα▲下４▼β▲下１▼のＶＣＡＭ−１またはフィブロネクチンへの結合を阻害する方法 |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| DE19515177A1 (de) | 1995-04-28 | 1996-10-31 | Cassella Ag | Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| ES2171768T3 (es) | 1996-03-20 | 2002-09-16 | Hoechst Ag | Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina. |
| SG158733A1 (en) | 1996-07-25 | 2010-02-26 | Biogen Idec Inc | Cell adhesion inhibitors |
| DE19647382A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| DE19647380A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| DE19647381A1 (de) | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
| WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| JP4555468B2 (ja) | 1997-10-31 | 2010-09-29 | アベンテイス・フアルマ・リミテツド | 置換アニリド |
| GB9723789D0 (en) * | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
| DE19751251A1 (de) * | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| WO1999054321A1 (en) | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
| DE19821483A1 (de) * | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| KR20010083081A (ko) * | 1998-06-30 | 2001-08-31 | 실버스타인 아써 에이. | 염증성질환, 자가면역질환 및 호흡기질환을 치료하는데유용한 브이엘에이-4-의존성 세포 결합의 비-펩티딜 억제제 |
| WO2000002903A1 (en) | 1998-07-10 | 2000-01-20 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
| DE19922462A1 (de) * | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
-
2001
- 2001-03-10 DE DE10111877A patent/DE10111877A1/de not_active Withdrawn
-
2002
- 2002-02-23 RS YUP-708/03A patent/RS51140B/sr unknown
- 2002-02-23 CZ CZ20032429A patent/CZ301893B6/cs not_active IP Right Cessation
- 2002-02-23 HU HU0303455A patent/HU228304B1/hu not_active IP Right Cessation
- 2002-02-23 AT AT02700268T patent/ATE293621T1/de active
- 2002-02-23 JP JP2002571489A patent/JP4482277B2/ja not_active Expired - Fee Related
- 2002-02-23 DE DE60203791T patent/DE60203791T2/de not_active Expired - Lifetime
- 2002-02-23 IL IL15783002A patent/IL157830A0/xx unknown
- 2002-02-23 BR BR0207981-0A patent/BR0207981A/pt active Search and Examination
- 2002-02-23 SI SI200230124T patent/SI1373249T1/xx unknown
- 2002-02-23 KR KR1020037011940A patent/KR100991678B1/ko not_active IP Right Cessation
- 2002-02-23 ME MEP-611/08A patent/MEP61108A/xx unknown
- 2002-02-23 AU AU2002233358A patent/AU2002233358B2/en not_active Ceased
- 2002-02-23 MX MXPA03007634A patent/MXPA03007634A/es active IP Right Grant
- 2002-02-23 RU RU2003129986/04A patent/RU2303592C2/ru not_active IP Right Cessation
- 2002-02-23 SK SK1126-2003A patent/SK286652B6/sk not_active IP Right Cessation
- 2002-02-23 PL PL362573A patent/PL204622B1/pl unknown
- 2002-02-23 DK DK02700268T patent/DK1373249T3/da active
- 2002-02-23 CA CA2440648A patent/CA2440648C/en not_active Expired - Fee Related
- 2002-02-23 NZ NZ528075A patent/NZ528075A/en not_active IP Right Cessation
- 2002-02-23 PT PT02700268T patent/PT1373249E/pt unknown
- 2002-02-23 ES ES02700268T patent/ES2240687T3/es not_active Expired - Lifetime
- 2002-02-23 CN CNB028063147A patent/CN1227248C/zh not_active Expired - Fee Related
- 2002-02-23 EP EP02700268A patent/EP1373249B1/en not_active Expired - Lifetime
- 2002-02-23 WO PCT/EP2002/001917 patent/WO2002072573A1/en active IP Right Grant
- 2002-02-23 EE EEP200300436A patent/EE05401B1/xx not_active IP Right Cessation
- 2002-03-07 AR ARP020100830A patent/AR035692A1/es active IP Right Grant
- 2002-03-08 PE PE2002000184A patent/PE20020904A1/es not_active Application Discontinuation
- 2002-03-08 US US10/092,901 patent/US6680333B2/en not_active Expired - Lifetime
- 2002-03-08 TW TW091104327A patent/TWI328587B/zh not_active IP Right Cessation
- 2002-03-08 MY MYPI20020824A patent/MY129029A/en unknown
-
2003
- 2003-08-07 ZA ZA200306107A patent/ZA200306107B/en unknown
- 2003-08-25 BG BG108134A patent/BG108134A/bg unknown
- 2003-09-08 HR HR20030713A patent/HRP20030713B1/xx not_active IP Right Cessation
- 2003-09-09 NO NO20033981A patent/NO326001B1/no not_active IP Right Cessation
- 2003-09-09 IL IL157830A patent/IL157830A/en not_active IP Right Cessation
-
2004
- 2004-06-11 HK HK04104237A patent/HK1062173A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE455788T1 (de) | Imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate | |
| MY118313A (en) | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | |
| MY123865A (en) | Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists | |
| MY118176A (en) | Heterocycles as inhibitors of leucocyte adhesion and as vla-4-antagonists | |
| MX9708782A (es) | Heterociclos de 5 anillos como inhibidores de la adhesion de leucocitos y antagonistas de vla-4. | |
| EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
| MY121745A (en) | 2,4-substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them. | |
| BRPI0512703A (pt) | composto ou um sal ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para o tratamento de uma condição ou doença inflamatória ou imune em um indivìduo e para a modulação da função cxcr3 | |
| MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
| MXPA05010824A (es) | Compuestos biciclicos como antagonistas del receptor nr2b. | |
| ATE461178T1 (de) | Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden | |
| IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| DK1725536T3 (da) | Imidazolin-derivater med CB1-antagonistisk aktivitet | |
| TW200616636A (en) | Novel compounds | |
| MY134191A (en) | Novel 5-membered ring heterocycles, their preparation their use and pharmaceutical preparations comprising them | |
| YU70803A (sh) | Derivati imidazolidina, njihovo dobijanje i njihova upotreba kao antiinflamatornih agensa | |
| TR200200125T2 (tr) | Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar. | |
| MXPA05010986A (es) | Compuestos de n-[(piperazinil)hetaril]arilsulfonamida con afinidad para el receptor d3 de la dopamina. | |
| MXPA04000041A (es) | Nuevos derivados de imidazolidina, su preparacion y su uso como antagonistas de vla-4. | |
| TR200103856T2 (tr) | Naftiridin türevleri, bunların preparasyon işlemleri, kullanımları ve farmasötik kompozisyonlar. | |
| TWI256386B (en) | Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | |
| SG146692A1 (en) | Melanin concentrating hormone antagonists | |
| MXPA05005340A (es) | Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen. | |
| DK1373218T3 (da) | Imidazolylderivater til anvendelse som histamin H3-receptorligander | |
| NO20020886L (no) | Nye integrin- <alfa>v<beta>3-inhibitorer |